KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Work In Process: 2013-2024

Historic Work In Process for Supernus Pharmaceuticals (SUPN) over the last 11 years, with Dec 2024 value amounting to $26.7 million.

  • Supernus Pharmaceuticals' Work In Process rose 18.88% to $33.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.4 million, marking a year-over-year increase of 18.88%. This contributed to the annual value of $26.7 million for FY2024, which is 14.38% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Work In Process of $26.7 million as of FY2024, which was down 14.38% from $31.2 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Work In Process high stood at $45.7 million for FY2021, and its period low was $9.0 million during FY2020.
  • For the 3-year period, Supernus Pharmaceuticals' Work In Process averaged around $29.9 million, with its median value being $31.2 million (2023).
  • Per our database at Business Quant, Supernus Pharmaceuticals' Work In Process spiked by 408.75% in 2021 and then plummeted by 30.63% in 2022.
  • Supernus Pharmaceuticals' Work In Process (Yearly) stood at $9.0 million in 2020, then skyrocketed by 408.75% to $45.7 million in 2021, then plummeted by 30.63% to $31.7 million in 2022, then fell by 1.57% to $31.2 million in 2023, then declined by 14.38% to $26.7 million in 2024.